Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Asmaa M A Bayoumi"'
Autor:
Fumihito Miura, Miki Miura, Yukiko Shibata, Yoshikazu Furuta, Keisuke Miyamura, Yuki Ino, Asmaa M. A. Bayoumi, Utako Oba, Takashi Ito
Publikováno v:
BMC Biotechnology, Vol 22, Iss 1, Pp 1-15 (2022)
Abstract Background DNA methyltransferases (MTases) are enzymes that induce methylation, one of the representative epigenetic modifications of DNA, and are also useful tools for analyzing epigenomes. However, regarding DNA cytosine 5-methylation, MTa
Externí odkaz:
https://doaj.org/article/a6e1eef97a8944bcb5609ba107e31c8d
Autor:
Fumihito Miura, Miki Miura, Yukiko Shibata, Yoshikazu Furuta, Keisuke Miyamura, Yuki Ino, Asmaa M. A. Bayoumi, Utako Oba, Takashi Ito
Publikováno v:
BMC Biotechnology, Vol 22, Iss 1, Pp 1-1 (2022)
Externí odkaz:
https://doaj.org/article/a546be7e87394aa38bead72155875e58
Autor:
Mohamed Raafat, Amr A. Kamel, Alaa H. Shehata, Al-Shaimaa F. Ahmed, Asmaa M. A. Bayoumi, Rabab A. Moussa, Mohammed A. S. Abourehab, Mahmoud El-Daly
Publikováno v:
Pharmaceuticals, Vol 15, Iss 2, p 130 (2022)
Background: Benign prostatic hyperplasia (BPH) is the most common urogenital condition in aging males, while inflammation and tissue proliferation constitute the main pathophysiological factors. The adverse effects of currently available BPH medicati
Externí odkaz:
https://doaj.org/article/20b304d01e7b4fe687ca44e61536e105
Autor:
Mohamed G. Ewees, Basim A. S. Messiha, Ali A. Abo-Saif, Asmaa M. A. Bayoumi, Mohamed S. Abdel-Bakky
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
Externí odkaz:
https://doaj.org/article/632e7a682cad4398aac3e754df14956d
Autor:
Mohamed G. Ewees, Basim A. S. Messiha, Ali A. Abo-Saif, Asmaa M. A. Bayoumi, Mohamed S. Abdel-Bakky
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
Coagulation system activation plays an important role in the pathophysiology of different diseases. In spite of massive research regarding cisplatin-induced nephrotoxicity, the role of coagulation cascade in such toxicity is still questionable. Here,
Externí odkaz:
https://doaj.org/article/6397077ecf8e42cdbf692410c1a3d02d
Autor:
Randa Ahmed Ibrahim, Sayed Shehata, Marwa M.M. Refaie, Seham A. Abdel-Gaber, Asmaa M A Bayoumi
Publikováno v:
Cardiovascular Toxicology. 21:1033-1044
Doxorubicin (DOX) is one of the most widely used chemotherapeutic drugs, but its cardiotoxicity has been shown to be a dose-restricting factor during therapy. Finding new agents for reducing these complications is still in critical need. The current
Autor:
Asmaa M A Bayoumi, Sayed Shehata, Marwa M.M. Refaie, Walaa Yehia Abdelzaher, Nashwa Fathy Gamal El-Tahawy
Publikováno v:
Cardiovascular Drugs and Therapy. 36:817-827
The cardiotoxicity of anticancer drugs such as 5-fluorouracil (5FU) is a major complication that challenges their clinical usefulness. Thus there is a critical need to find new protective drugs to defend against these harmful side effects. Up to now,
Autor:
Marwa M M, Refaie, Sayed, Shehata, Randa Ahmed, Ibrahim, Asmaa M A, Bayoumi, Seham A, Abdel-Gaber
Publikováno v:
Cardiovascular toxicology. 21(12)
Doxorubicin (DOX) is one of the most widely used chemotherapeutic drugs, but its cardiotoxicity has been shown to be a dose-restricting factor during therapy. Finding new agents for reducing these complications is still in critical need. The current
Autor:
Marwa M M, Refaie, Sayed, Shehata, Asmaa M A, Bayoumi, Nashwa Fathy Gamal, El-Tahawy, Walaa Yehia, Abdelzaher
Publikováno v:
Cardiovascular drugs and therapy. 36(5)
The cardiotoxicity of anticancer drugs such as 5-fluorouracil (5FU) is a major complication that challenges their clinical usefulness. Thus there is a critical need to find new protective drugs to defend against these harmful side effects. Up to now,
Autor:
Marwa M M, Refaie, Sayed, Shehata, Maram, El-Hussieny, Wedad M, Abdelraheem, Asmaa M A, Bayoumi
Publikováno v:
Cardiovascular toxicology. 20(1)
Cyclophosphamide (CP) is a widely used chemotherapeutic agent but its clinical usefulness is challenged with different forms of toxicities. No studies have evaluated the possible protective effect of nicorandil (NIC) in CP-induced cardiotoxicity. Our